Category Archives: IP Rights

Why RCEP is the problem, not the solution

Source: inquirer.net | May 17, 2017 On May 2-12, the 16 member-countries of the Regional Comprehensive Economic Partnership (RCEP) met in Manila for their 18th round of negotiations to craft a multilateral trade deal that would affect half of the world’s … Continue reading

Posted in Investor state dispute, IP Rights, ISDS, Regional Comprehensive Economic Partnership, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Trade laws that rob common people

Dr Gopal Dabade, Deccan Herald|  May 8 2017 If the RCEP talks materialise, they will give big companies a market access to over 3 billion people. Trade between countries has existed since time immemorial. The World Tr­ade Organisation (WTO) is … Continue reading

Posted in Investor state dispute, IPR Enforcement, ISDS, Regional Comprehensive Economic Partnership, TRIPS plus, Uncategorized, WTO | Leave a comment

MSF response on RCEP negotiations in the Philippines

Source: MSF Access Campaign New Delhi, 8 May 2017 – The Philippines is set to host the 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement’s negotiations in Manila this week. Negotiators from the ten members of the … Continue reading

Posted in Data Exclusivity, Evergreening, Investor state dispute, IPR Enforcement, ISDS, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized, WTO | Leave a comment

Indian pharma at odds with US trade group over USTR Priority Watch List

The tug of war continues. Even as the Indian Pharmaceutical Alliance, the domestic drug industry lobby group, has appealed to the US Trade Representative to remove India from its Priority Watch List – the latter includes countries that are alleged … Continue reading

Posted in IP Rights, IPR, IPR policy, Special 301 report, Uncategorized, USTR 301 report | Leave a comment

European Commission publishes negotiating proposals for EU-Indonesia trade deal

It is important to note that the EU proposals on IP are TRIPS-plus in multiple regards and would surely reduce policy space in Indonesia and negatively impact access to affordable medicines.  Even a preliminary review of the proposal reveals: A … Continue reading

Posted in IPR Enforcement, Patent Term Extension, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Can drug firms increase health-care access, or just their profits?

Anne Aerts, head of Novartis Foundation, addresses a conference in Basel, Switzerland, looking at the role of drug companies in building health systems. (Credit: Kiara Barnes/Novartis) BASEL, Switzerland — The controversial Swiss pharmaceutical company Novartis has started work to expand … Continue reading

Posted in Drug prices, Novartis Case, Uncategorized | 2 Comments

In pics: Delhi Network of Positive People at Embassies of RCEP negotiating countries

As the next Regional Comprehensive Economic Partnership (RCEP) trade agreement rounds are set to take place in Tianjin, China, from 17-21 October, Delhi Network of Positive People urges all the negotiating countries to reject any terms in the deal that … Continue reading

Posted in Data Exclusivity, FTA, IPR Enforcement, Regional Comprehensive Economic Partnership, TPP, TRIPS plus, Uncategorized | Leave a comment